Aug 07, 2019 / 06:30PM GMT
Kyle William Rose - Canaccord Genuity Corp., Research Division - Senior Analyst
Continue on with the diabetes team this afternoon but transition over to insulin delivery. So next up we have Insulet, who is a top player on the insulin pump market, with what we believe is a very novel and differentiated both form factor and business model. So the company just reported -- we really think it's driven by the innovative new product cycle in DASH but also what we view as kind of a Trojan horse in the diabetes space, which is the shift to the pharmacy model. So I'm very excited
to have Insulet with us this afternoon. And presenting on behalf of Insulet is Bret Christensen,
the Chief Commercial Officer. We also have Deb Gordon, the Vice President of IR and Corporate Communications, in the audience as well.
So without any further ado, I will pass it over to Bret. Thank you.
Bret Christensen - Insulet Corporation - Executive VP & Chief Commercial Officer
Thanks, Kyle. Good afternoon, everyone. It is great to be here to talk about Insulet
Insulet Corp at Canaccord Genuity Growth Conference Transcript
Aug 07, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers